{"id":473,"date":"2024-10-16T09:17:00","date_gmt":"2024-10-16T06:17:00","guid":{"rendered":"https:\/\/softeducational.ro\/?p=473"},"modified":"2026-05-28T09:18:55","modified_gmt":"2026-05-28T06:18:55","slug":"red-insuficienta-cardiaca","status":"publish","type":"post","link":"https:\/\/softeducational.ro\/index.php\/2024\/10\/16\/red-insuficienta-cardiaca\/","title":{"rendered":"RED &#8211; Insuficien\u021ba cardiac\u0103"},"content":{"rendered":"\n<p><strong><u>Insuficien\u021ba cardiac\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Defini\u021bie<\/u><\/strong> Insuficien\u021ba cardiac\u0103 este incapacitatea func\u021biei cardiace de a asigura un debit cardiac suficient pentru necesit\u0103\u021bile metabolice ale organismului, \u00een condi\u021biile unei presiuni venoase normale \u0219i a unei reveniri venoase adecvate.<\/p>\n\n\n\n<p><strong><u>Principii fiziopatologice esen\u021biale<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Sc\u0103derea debitului cardiac determin\u0103 hipoperfuzie tisular\u0103 \u0219i activare neurohormonal\u0103.<\/li>\n\n\n\n<li>Congestia venoas\u0103 apare prin acumularea retrograd\u0103 a s\u00e2ngelui \u00een teritoriile venoase aferente ventriculilor afecta\u021bi.<\/li>\n\n\n\n<li>Remodelarea cardiac\u0103 (dilatare, hipertrofie) este at\u00e2t cauz\u0103, c\u00e2t \u0219i consecin\u021b\u0103 a disfunc\u021biei ventriculare.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Clasificare clinic\u0103 \u0219i func\u021bional\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Tipuri anatomice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Insuficien\u021b\u0103 cardiac\u0103 st\u00e2ng\u0103<\/strong> \u2014 predomin\u0103 semnele de congestie pulmonar\u0103 \u0219i sc\u0103derea debitului cardiac.<\/li>\n\n\n\n<li><strong>Insuficien\u021b\u0103 cardiac\u0103 dreapt\u0103<\/strong> \u2014 predomin\u0103 semnele de staz\u0103 venoas\u0103 sistemic\u0103 (jugulare turgescente, hepatomegalie, edeme).<\/li>\n\n\n\n<li><strong>Insuficien\u021b\u0103 cardiac\u0103 global\u0103<\/strong> \u2014 coexist\u0103 semnele de insuficien\u021b\u0103 st\u00e2ng\u0103 \u0219i dreapt\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Tipuri func\u021bionale dup\u0103 frac\u021bia de ejec\u021bie<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>IC cu frac\u021bie de ejec\u021bie redus\u0103<\/strong> \u2014 disfunc\u021bie sistolic\u0103 a ventriculului st\u00e2ng, FE \u2264 40%, frecvent cu dilatarea VS.<\/li>\n\n\n\n<li><strong>IC cu frac\u021bie de ejec\u021bie p\u0103strat\u0103<\/strong> \u2014 func\u021bie sistolic\u0103 normal\u0103 sau u\u0219or redus\u0103 (FE 40\u201350%), cu disfunc\u021bie diastolic\u0103 \u0219i ventricul st\u00e2ng de dimensiuni normale sau hipertrofiat.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Durata \u0219i evolu\u021bia<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Acut\u0103<\/strong> \u2014 debut rapid sau agravare brusc\u0103 a simptomelor, necesit\u0103 interven\u021bie imediat\u0103.<\/li>\n\n\n\n<li><strong>Cronic\u0103<\/strong> \u2014 evolu\u021bie lent\u0103, cu perioade decompensate \u0219i compensate.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Stadiile evolutive moderne ale insuficien\u021bei cardiace<\/u><\/strong><\/p>\n\n\n\n<p><strong>Stadiul A<\/strong> Risc crescut de apari\u021bie a IC, f\u0103r\u0103 anomalii structurale cardiace. Exemple: hipertensiune arterial\u0103, boal\u0103 coronarian\u0103, diabet, consum cronic de alcool, antecedente familiale de cardiomiopatie.<\/p>\n\n\n\n<p><strong>Stadiul B<\/strong> Anomalii structurale cardiace prezente, f\u0103r\u0103 simptomatologie. Exemple: dilatare ventricular\u0103, leziuni valvulare, antecedent de infarct miocardic.<\/p>\n\n\n\n<p><strong>Stadiul C<\/strong> Simptome actuale sau anterioare de IC asociate cu anomalii structurale. Pacien\u021bi trata\u021bi pentru simptome de insuficien\u021b\u0103 ventricular\u0103.<\/p>\n\n\n\n<p><strong>Stadiul D<\/strong> Boal\u0103 terminal\u0103, refractar\u0103 la tratamente conven\u021bionale; necesit\u0103 terapie avansat\u0103 (transplant, dispozitive mecanice, \u00eengrijire paliativ\u0103 complex\u0103).<\/p>\n\n\n\n<p><strong><u>Etiologie \u0219i factori predispozan\u021bi<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Cauze principale<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Cardiopatie ischemic\u0103<\/strong> (infarct miocardic, ischemie cronic\u0103)<\/li>\n\n\n\n<li><strong>Hipertensiune arterial\u0103<\/strong> (presiune crescut\u0103 de \u00eenc\u0103rcare)<\/li>\n\n\n\n<li><strong>Valvulopatii<\/strong> (stenoze sau insuficien\u021be valvulare)<\/li>\n\n\n\n<li><strong>Cardiomiopatii<\/strong> (dilatative, hipertrofice, restrictive)<\/li>\n\n\n\n<li><strong>Miocardite<\/strong> (infec\u021bioase, toxice, autoimune)<\/li>\n\n\n\n<li><strong>Tulbur\u0103ri metabolice<\/strong> (hipertiroidism, anemii severe, deficite nutritive)<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Cauze mecanice \u0219i inflamatorii<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Cauzele mecanice afecteaz\u0103 ini\u021bial dinamica valvular\u0103 sau de volum (valvulopatii, disec\u021bie aortic\u0103).<\/li>\n\n\n\n<li>Procesele inflamatorii sau metabolice afecteaz\u0103 direct miocardul (miocardit\u0103, cardiomiopatie ischemic\u0103).<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Factori precipitan\u021bi ai decompens\u0103rii<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Nonadheren\u021ba la tratament<\/strong> sau la regim (sare, lichide)\u2192nerespectarea<\/li>\n\n\n\n<li><strong>Aritmii<\/strong> cu frecven\u021b\u0103 rapid\u0103 sau bradicardie sever\u0103<\/li>\n\n\n\n<li><strong>Infec\u021bii acute<\/strong> (pneumonie, endocardit\u0103)<\/li>\n\n\n\n<li><strong>Ischemie acut\u0103 coronarian\u0103<\/strong> sau complica\u021bii postinfarct<\/li>\n\n\n\n<li><strong>Embolie pulmonar\u0103<\/strong> sau tamponad\u0103 cardiac\u0103<\/li>\n\n\n\n<li><strong>Sarcina, na\u0219terea, efort fizic intens<\/strong><\/li>\n\n\n\n<li><strong>Medica\u021bie cu efect inotrop negativ<\/strong> sau interac\u021biuni medicamentoase<\/li>\n\n\n\n<li><strong>Insuficien\u021b\u0103 renal\u0103 acut\u0103<\/strong> sau dezechilibre hidroelectrolitice<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Insuficien\u021ba cardiac\u0103 st\u00e2ng\u0103 \u2014 semne \u0219i simptome<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Simptome cardinale<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Dispnee de efort<\/strong> \u2014 simptom principal, reflect\u0103 staza veno-capilar\u0103 pulmonar\u0103 \u0219i sc\u0103derea capacit\u0103\u021bii de schimb gazos.<\/li>\n\n\n\n<li><strong>Ortopenie<\/strong> \u0219i <strong>dispnee de repaus<\/strong> \u00een formele avansate.<\/li>\n\n\n\n<li><strong>Tuse<\/strong> iritativ\u0103, posibil\u0103 expectora\u021bie seroas\u0103 sau spumoas\u0103; hemoptizie \u00een cazuri severe.<\/li>\n\n\n\n<li><strong>Astenie, fatigabilitate<\/strong> \u2014 datorate hipoperfuziei musculare \u0219i redistribu\u021biei debitului.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Semne obiective<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Raluri subcrepitante<\/strong> la bazele pulmonare; wheezing \u00een context de bronhospasm cardiogen.<\/li>\n\n\n\n<li><strong>Edem pulmonar acut<\/strong> \u2014 dispnee sever\u0103, hipoxemie, expectora\u021bie spumoas\u0103 rozat\u0103, tahipnee, anxietate.<\/li>\n\n\n\n<li><strong>Puls mic<\/strong> sau puls alternat \u00een forme grave.<\/li>\n\n\n\n<li><strong>Deplasarea v\u00e2rfului cordului<\/strong> spre st\u00e2nga \u0219i \u00een jos \u00een cardiomegalie.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Complica\u021bii respiratorii acute<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Astmul cardiac<\/strong> \u2014 acces paroxistic de dispnee cu wheezing, diferen\u021biat de astmul bron\u0219ic prin contextul cardiologic.<\/li>\n\n\n\n<li><strong>Edem pulmonar acut cardiogen<\/strong> \u2014 urgen\u021b\u0103 medical\u0103, necesit\u0103 deple\u021bie volemic\u0103 rapid\u0103 \u0219i suport respirator.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Insuficien\u021ba cardiac\u0103 dreapt\u0103 \u2014 semne \u0219i simptome<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Semne clinice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Jugulare turgescente<\/strong> \u0219i hipertensiune venoas\u0103 sistemic\u0103.<\/li>\n\n\n\n<li><strong>Hepatomegalie dureroas\u0103<\/strong> cu posibil reflux hepatojugular.<\/li>\n\n\n\n<li><strong>Edeme periferice<\/strong> bilaterale, predominante \u00een zonele declive (pretibial, retromaleolar, presacrat).<\/li>\n\n\n\n<li><strong>Anasarc\u0103<\/strong> \u0219i rev\u0103rsate seroase \u00een cavit\u0103\u021bi (pleur\u0103, peritoneu, pericard).- edem generalizat<\/li>\n\n\n\n<li><strong>Cianoz\u0103 periferic\u0103<\/strong> prin \u00eencetinirea circula\u021biei.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Semne cardiace specifice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Matitate cardiac\u0103 crescut\u0103<\/strong> la percu\u021bie; pulsa\u021bii epigastrice ale VD.<\/li>\n\n\n\n<li><strong>Galop xifoidian<\/strong> \u0219i suflu tricuspidian \u00een insuficien\u021ba tricuspidian\u0103 secundar\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Context etiologic<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Poate fi izolat\u0103 (ex. embolie pulmonar\u0103 acut\u0103) sau secundar\u0103 decompens\u0103rii st\u00e2ngi (consecin\u021b\u0103 a hipertensiunii pulmonare).<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Examenul clinic al pacientului cu insuficien\u021b\u0103 cardiac\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Aspecte esen\u021biale de evaluat<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Semne vitale: tensiune arterial\u0103, frecven\u021b\u0103 cardiac\u0103, satura\u021bie oxigen.<\/li>\n\n\n\n<li>Semne de congestie pulmonar\u0103 \u0219i sistemic\u0103.<\/li>\n\n\n\n<li>Prezen\u021ba galopului, suflurilor, modificarea impulsului apexian.<\/li>\n\n\n\n<li>Semne de hipoperfuzie: paloare, confuzie, oligurie.<\/li>\n\n\n\n<li>Evaluarea edemelor \u0219i a semnelor de reten\u021bie hidric\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Investiga\u021bii paraclinice ini\u021biale<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Laborator<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Hemoleucogram\u0103, ionograme, func\u021bie renal\u0103, transaminaze, timp de protrombin\u0103.<\/li>\n\n\n\n<li>Markeri inflamatori \u0219i func\u021bie tiroidian\u0103 c\u00e2nd este indicat.<\/li>\n\n\n\n<li><strong>Dozarea peptide natriuretice<\/strong> (BNP, NT-proBNP) are valoare diagnostic\u0103 \u0219i prognostic\u0103 \u00een insuficien\u021ba cardiac\u0103; praguri de excludere difer\u0103 \u00een func\u021bie de context clinic.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Gaze sanguine arteriale \u0219i puls-oximetrie<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Evaluarea oxigen\u0103rii \u0219i a statusului acido-bazic; puls-oximetria nu \u00eenlocuie\u0219te analiza gazelor pentru PaCO\u2082 \u0219i pH.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Electrocardiogram\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Obligatorie la to\u021bi pacien\u021bii: poate eviden\u021bia hipertrofie ventricular\u0103, semne de ischemie, unde Q de necroz\u0103, tulbur\u0103ri de ritm sau blocuri de conducere.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Radiografie toracic\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Evaluarea cardiomegaliei, stazei pulmonare \u0219i a eventualelor rev\u0103rsate pleurale.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Monitorizare hemodinamic\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Cateterismul pulmonar (Swan-Ganz) pentru m\u0103surarea presiunilor \u00een cazuri selec\u021bionate (evaluare hemodinamic\u0103 complex\u0103).<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Ecocardiografie \u0219i imagistic\u0103 cardiac\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Ecocardiografie transtoracic\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Evaluarea dimensiunilor cavit\u0103\u021bilor, grosimii pere\u021bilor, func\u021biei sistolice \u0219i diastolice, frac\u021biei de ejec\u021bie, \u0219i a regurgit\u0103rilor valvulare.<\/li>\n\n\n\n<li>Frac\u021bia de ejec\u021bie normal\u0103 considerat\u0103 &gt; 50%.<\/li>\n\n\n\n<li>Tehnici avansate (Doppler tisular, speckle tracking) permit detectarea precoce a disfunc\u021biei ventriculare.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Ecocardiografie transesofagian\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Indica\u021bii: evaluarea complex\u0103 a valvulopatiilor, suspiciune de endocardit\u0103, imagini transtoracice neconcludente.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Investiga\u021bii complementare<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Test de efort pentru evaluarea ischemiei \u0219i capacit\u0103\u021bii func\u021bionale.<\/li>\n\n\n\n<li>Holter pentru detectarea aritmiilor.<\/li>\n\n\n\n<li>Coronarografie c\u00e2nd se suspecteaz\u0103 boal\u0103 coronarian\u0103 semnificativ\u0103.<\/li>\n\n\n\n<li>CT coronarian, SPECT, PET, RMN cardiac sau biopsie endomiocardic\u0103 \u00een cazuri selec\u021bionate pentru diagnostic diferen\u021bial sau etiologic.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Biomarkeri utili \u00een insuficien\u021ba cardiac\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Peptide natriuretice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>BNP<\/strong> \u0219i <strong>NT-proBNP<\/strong> cresc \u00een prezen\u021ba insuficien\u021bei cardiace; sunt utile pentru diagnostic \u0219i monitorizare.<\/li>\n\n\n\n<li>Valorile prag pentru excludere variaz\u0103 \u00een func\u021bie de context (debut acut vs. debut progresiv) \u0219i de comorbidit\u0103\u021bi.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Complica\u021bii ale insuficien\u021bei cardiace<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Complica\u021bii hemodinamice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Hipoperfuzie tisular\u0103 cu insuficien\u021b\u0103 renal\u0103 func\u021bional\u0103 \u0219i tulbur\u0103ri metabolice.<\/li>\n\n\n\n<li>\u0218oc cardiogen \u00een formele severe, cu risc crescut de mortalitate.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Complica\u021bii tromboembolice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Tromboze intracavitare \u0219i embolii sistemice sau pulmonare.<\/li>\n\n\n\n<li>Tromboza venoas\u0103 profund\u0103 favorizat\u0103 de imobilizare prelungit\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Complica\u021bii viscerale \u0219i infec\u021bioase<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Ciroz\u0103 cardiac\u0103 prin staz\u0103 hepatic\u0103 cronic\u0103.<\/li>\n\n\n\n<li>Infec\u021bii bronhopulmonare recurente datorate stazei pulmonare.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Complica\u021bii iatrogene \u0219i metabolice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Tulbur\u0103ri hidroelectrolitice \u0219i reac\u021bii adverse medicamentoase.<\/li>\n\n\n\n<li>Intoxica\u021bie digitalic\u0103 \u00een cazul utiliz\u0103rii digitalei.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Principii generale de tratament<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Obiective terapeutice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Ameliorarea simptomelor \u0219i a calit\u0103\u021bii vie\u021bii.<\/li>\n\n\n\n<li>Corectarea factorilor precipitanti \u0219i a comorbidit\u0103\u021bilor.<\/li>\n\n\n\n<li>Prevenirea progresiei bolii \u0219i a spitaliz\u0103rilor repetate.<\/li>\n\n\n\n<li>Reducerea mortalit\u0103\u021bii \u00een formele cronice.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Abordare multimodal\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>M\u0103suri non\u2011farmacologice (regim, activitate, educa\u021bie).<\/li>\n\n\n\n<li>Terapie farmacologic\u0103 ghidat\u0103 de clas\u0103 \u0219i severitate.<\/li>\n\n\n\n<li>Interven\u021bii invazive sau dispozitive c\u00e2nd sunt indicate.<\/li>\n\n\n\n<li>Monitorizare continu\u0103 \u0219i reevaluare periodic\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Regim igieno\u2011dietetic \u0219i m\u0103suri nonfarmacologice<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Repaus \u0219i activitate fizic\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Adaptarea nivelului de activitate la capacitatea func\u021bional\u0103; repaus relativ \u00een perioadele decompensate.<\/li>\n\n\n\n<li>Program de reabilitare cardiac\u0103 \u0219i antrenament fizic supravegheat pentru pacien\u021bii stabili.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Regim alimentar \u0219i lichide<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Diet\u0103 hiposodat\u0103; restric\u021bie de lichide \u00een formele severe cu reten\u021bie hidric\u0103.<\/li>\n\n\n\n<li>Controlul greut\u0103\u021bii corporale \u0219i al aportului caloric la pacien\u021bii obezi.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Stil de via\u021b\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Renun\u021barea la fumat; limitarea consumului de alcool.<\/li>\n\n\n\n<li>Vaccin\u0103ri recomandate (influentae, pneumococ) pentru reducerea riscului de infec\u021bii respiratorii.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Educa\u021bie \u0219i aderen\u021b\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Informarea pacientului privind semnele de alarm\u0103, monitorizarea greut\u0103\u021bii \u0219i respectarea tratamentului.<\/li>\n\n\n\n<li>Evaluarea \u0219i sus\u021binerea aderen\u021bei la terapie.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Farmacoterapie \u2014 clase terapeutice \u0219i indica\u021bii<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Diuretice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Utilizate pentru controlul congestiei \u0219i reducerea edemelor; alegerea tipului \u0219i dozei se face individualizat \u0219i sub monitorizare.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Inhibitori ai enzimei de conversie a angiotensinei \u0219i blocan\u021bi ai receptorilor pentru angiotensin\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Reduc \u00eenc\u0103rcarea hemodinamic\u0103 \u0219i au efecte favorabile asupra prognosticului \u00een multe forme de IC.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Blocan\u021bi beta<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Indica\u021bi pentru controlul frecven\u021bei cardiace \u0219i pentru reducerea remodel\u0103rii cardiace \u00een formele cronice stabile.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Antagonisti ai receptorilor mineralocorticoizi<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Utili \u00een reducerea reten\u021biei de sodiu \u0219i a remodel\u0103rii, \u00een anumite categorii de pacien\u021bi.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Inhibitori SGLT2 &#8211; <\/u><\/strong><strong><em><u>Inhibitorii SGLT2 (gliflozinele) sunt o clas\u0103 de medicamente care blocheaz\u0103 reabsorb\u021bia glucozei la nivel renal, determin\u00e2nd eliminarea ei \u00een urin\u0103; ini\u021bial folosi\u021bi pentru diabetul zaharat tip 2, \u00eens\u0103 au demonstrat \u0219i beneficii cardiovasculare \u0219i renale \u00een anumite categorii de pacien\u021bi.<\/u><\/em><\/strong><em><u><\/u><\/em><\/p>\n\n\n\n<ul>\n<li>Au demonstrat beneficii \u00een reducerea spitaliz\u0103rilor pentru IC \u0219i \u00een \u00eembun\u0103t\u0103\u021birea prognosticului la pacien\u021bii selecta\u021bi.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Vasodilatatoare<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Nitra\u021bii \u0219i al\u021bi vasodilatatori pot fi utiliza\u021bi pentru reducerea presarcinii \u0219i a post\u2011sarcinii \u00een situa\u021bii specifice.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Anticoagulare \u0219i antiagregare<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Indicate conform riscului tromboembolic \u0219i prezen\u021bei fibrila\u021biei atriale sau a trombilor intracavitari.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Digitalice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Pot fi folosite pentru controlul frecven\u021bei \u00een fibrila\u021bia atrial\u0103 \u0219i pentru ameliorarea simptomelor la pacien\u021bii selecta\u021bi; monitorizarea este esen\u021bial\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong>Not\u0103<\/strong> Alegerea \u0219i dozarea medicamentelor trebuie realizate de medicul curant, \u00een func\u021bie de comorbidit\u0103\u021bi, func\u021bia renal\u0103 \u0219i toleran\u021b\u0103.<\/p>\n\n\n\n<p><strong><u>Managementul insuficien\u021bei cardiace acute \u2014 principii de urgen\u021b\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Stabilizare ini\u021bial\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Asigurarea c\u0103ilor respiratorii, oxigenoterapie pentru corectarea hipoxemiei \u0219i monitorizare hemodinamic\u0103.<\/li>\n\n\n\n<li>Pozi\u021bionare semisez\u00e2nd\u0103 pentru reducerea congestiei pulmonare.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Reducerea congestiei<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Diuretice cu ac\u021biune rapid\u0103 pentru deple\u021bia volemic\u0103 controlat\u0103.<\/li>\n\n\n\n<li>Vasodilatatoare intravenoase \u00een cazurile cu tensiune arterial\u0103 adecvat\u0103 pentru a reduce presarcina.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Suport hemodinamic<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>\u00cenotropi intraveno\u0219i pot fi necesari la pacien\u021bii cu hipoperfuzie sever\u0103; utilizarea se face sub monitorizare intensiv\u0103.<\/li>\n\n\n\n<li>Corectarea factorilor precipitanti: tratament pentru ischemie acut\u0103, controlul aritmiilor, tratamentul infec\u021biilor.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Tratament specific pentru edemul pulmonar acut<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Combina\u021bie de m\u0103suri: oxigen, diurez\u0103, vasodilatatoare \u0219i, dac\u0103 este necesar, suport ventilator.<\/li>\n\n\n\n<li>Monitorizare atent\u0103 a diurezei, electrolitilor \u0219i func\u021biei renale.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Anticoagulante \u0219i preven\u021bie tromboembolic\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Evaluare rapid\u0103 a indica\u021biei pentru anticoagulante \u00een func\u021bie de etiologie \u0219i risc.<\/li>\n<\/ul>\n\n\n\n<p><strong>Not\u0103<\/strong> Interven\u021biile de urgen\u021b\u0103 trebuie efectuate \u00een unit\u0103\u021bi cu resurse adecvate \u0219i personal instruit.<\/p>\n\n\n\n<p><strong><u>Interven\u021bii invazive \u0219i terapii avansate<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Revascularizare coronarian\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Indicat\u0103 c\u00e2nd ischemia coronarian\u0103 este substratul insuficien\u021bei cardiace \u0219i poate \u00eembun\u0103t\u0103\u021bi func\u021bia ventricular\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Corec\u021bia valvular\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Repararea sau \u00eenlocuirea valvelor \u00een valvulopatii severe care contribuie la insuficien\u021b\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Terapie cu dispozitive<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Terapia de resincronizare cardiac\u0103 pentru pacien\u021bii selecta\u021bi cu disfunc\u021bie sistolic\u0103 \u0219i bloc de ramur\u0103.<\/li>\n\n\n\n<li>Implant de defibrilator la pacien\u021bii cu risc crescut de aritmii ventriculare fatale.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Suport mecanic circulator<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Dispozitive de asistare ventricular\u0103 sau balon intraaortic \u00een cazuri selec\u021bionate, ca punte c\u0103tre transplant sau ca terapie de lung\u0103 durat\u0103.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Transplant cardiac<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Op\u021biune pentru pacien\u021bii cu boal\u0103 terminal\u0103 refractar\u0103 la tratamente conven\u021bionale.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Monitorizare \u0219i urm\u0103rire pe termen lung<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Parametri de monitorizat<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Greutatea corporal\u0103 zilnic\u0103, semnele de congestie, tensiunea arterial\u0103, frecven\u021ba cardiac\u0103 \u0219i func\u021bia renal\u0103.<\/li>\n\n\n\n<li>Evalu\u0103ri periodice prin ecocardiografie \u0219i doz\u0103ri de biomarkeri conform indica\u021biilor clinice.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Plan de urm\u0103rire<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Vizite programate pentru ajustarea terapiei, educa\u021bie \u0219i reabilitare cardiac\u0103.<\/li>\n\n\n\n<li>Acces rapid la evaluare \u00een caz de agravare a simptomelor.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Coordonare multidisciplinar\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Implicarea cardiologului, medicului de familie, nutri\u021bionistului, fizioterapeutului \u0219i, c\u00e2nd este cazul, a echipei de transplant sau a serviciilor paliative.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Preven\u021bie primar\u0103 \u0219i secundar\u0103<\/u><\/strong><\/p>\n\n\n\n<p><strong><u>Preven\u021bie primar\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Controlul factorilor de risc cardiovascular: hipertensiune, diabet, dislipidemie, fumat, obezitate.<\/li>\n\n\n\n<li>Screening \u0219i tratament precoce al bolii coronariene \u0219i al valvulopatiilor.<\/li>\n<\/ul>\n\n\n\n<p><strong><u>Preven\u021bie secundar\u0103<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li>Optimizarea terapiei farmacologice pentru a preveni decompens\u0103rile.<\/li>\n\n\n\n<li>Educa\u021bie pentru recunoa\u0219terea semnelor de agravare \u0219i pentru aderen\u021ba la tratament.<\/li>\n<\/ul>\n\n\n\n<p><strong>Sumar schematic<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><td><strong>Tema<\/strong><\/td><td><strong>Semne cheie<\/strong><\/td><td><strong>M\u0103suri ini\u021biale<\/strong><\/td><td><strong>Tratament cronic<\/strong><\/td><\/tr><\/thead><tbody><tr><td>IC st\u00e2ng\u0103<\/td><td>Dispnee, raluri, edem pulmonar<\/td><td>Oxigen, diuretice, vasodilatatoare<\/td><td>IECA\/ARB, beta\u2011blocant, MRA, SGLT2<\/td><\/tr><tr><td>IC dreapt\u0103<\/td><td>Jugulare turgide, edeme, hepatomegalie<\/td><td>Diurez\u0103, corectare cauz\u0103<\/td><td>Tratarea cauzei, diuretice, anticoagulare<\/td><\/tr><tr><td>IC acut\u0103<\/td><td>Debut rapid, hipoxemie, instabilitate<\/td><td>Stabilizare, diurez\u0103, inotropi dac\u0103 e necesar<\/td><td>Reevaluare, optimizare terapie cronic\u0103<\/td><\/tr><tr><td>Preven\u021bie<\/td><td>Factori de risc<\/td><td>Educa\u021bie, vaccinare<\/td><td>Control factorilor de risc, reabilitare<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong><u>Concluzii \u0219i recomand\u0103ri practice<\/u><\/strong><\/p>\n\n\n\n<ul>\n<li><strong>Evaluarea corect\u0103 \u0219i tratamentul precoce<\/strong> reduc morbiditatea \u0219i spitaliz\u0103rile.<\/li>\n\n\n\n<li><strong>Abordarea integrat\u0103<\/strong> (regim, farmacoterapie, interven\u021bii) este esen\u021bial\u0103 pentru controlul bolii.<\/li>\n\n\n\n<li><strong>Educa\u021bia pacientului<\/strong> \u0219i monitorizarea continu\u0103 sunt piloni ai managementului eficient.<\/li>\n\n\n\n<li>Orice decizie terapeutic\u0103 specific\u0103, inclusiv alegerea medicamentelor \u0219i dozarea, trebuie luat\u0103 de medicul curant pe baza evalu\u0103rii clinice complete.<\/li>\n<\/ul>\n\n\n\n<p><strong>Bibliografie:<\/strong><\/p>\n\n\n\n<ol type=\"1\">\n<li><strong>European Society of Cardiology.<\/strong> ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure; 2021.<\/li>\n\n\n\n<li><strong>American College of Cardiology \/ American Heart Association.<\/strong> Guideline for the Management of Heart Failure; 2022.<\/li>\n\n\n\n<li><strong>Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine.<\/strong> Edi\u021bie recent\u0103; Elsevier.<\/li>\n\n\n\n<li><strong>Harrison\u2019s Principles of Internal Medicine.<\/strong> Capitolul despre insuficien\u021ba cardiac\u0103; edi\u021bie recent\u0103.<\/li>\n\n\n\n<li><strong>European Heart Journal.<\/strong> Review articles on heart failure, pathophysiology and management (select recent revizii).<\/li>\n\n\n\n<li><strong>Journal of the American College of Cardiology (JACC).<\/strong> Review articles and clinical updates privind insuficien\u021ba cardiac\u0103.<\/li>\n\n\n\n<li><strong>Circulation.<\/strong> Articole de revizuire \u0219i ghiduri clinice relevante pentru insuficien\u021ba cardiac\u0103.<\/li>\n\n\n\n<li><strong>UpToDate.<\/strong> Sec\u021biuni clinice privind diagnosticul \u0219i tratamentul insuficien\u021bei cardiace (resurs\u0103 pentru actualiz\u0103ri practice).<\/li>\n\n\n\n<li><strong>Ghiduri \u0219i protocoale locale\/spitalice\u0219ti.<\/strong> Protocoale de urgen\u021b\u0103 \u0219i management al edemului pulmonar (unit\u0103\u021bi clinice relevante).<\/li>\n\n\n\n<li><strong>Revizii \u0219i meta-analize privind SGLT2 inhibitors \u0219i insuficien\u021ba cardiac\u0103.<\/strong> Articole recente \u00een jurnale cardiologice pentru date despre beneficiile cardiovasculare \u0219i renale.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Insuficien\u021ba cardiac\u0103 Defini\u021bie Insuficien\u021ba cardiac\u0103 este incapacitatea func\u021biei cardiace de a asigura un debit cardiac suficient pentru necesit\u0103\u021bile metabolice ale organismului, \u00een condi\u021biile unei presiuni venoase normale \u0219i a unei&#8230; <\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"_links":{"self":[{"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/posts\/473"}],"collection":[{"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/comments?post=473"}],"version-history":[{"count":1,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/posts\/473\/revisions"}],"predecessor-version":[{"id":474,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/posts\/473\/revisions\/474"}],"wp:attachment":[{"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/media?parent=473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/categories?post=473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/softeducational.ro\/index.php\/wp-json\/wp\/v2\/tags?post=473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}